Bronchorus

Quick links to important sections

Bronchorus

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bronchorus

Quick Facts

Property Description
Active ingredient Ambroxol hydrochloride
Form Tablets, Syrup, Oral Solution, Inhalation Solution
Pharmacological class Mucolytic and Secretolytic Agent
General purpose To thin and clear mucus to relieve chest congestion
Origin Synthetic (derivative of Bromhexine)

What is Bronchorus? Definition and Pharmacological Class

Bronchorus is a pharmaceutical preparation whose primary function is to help clear the airways of thick, built-up mucus. The active ingredient in this medicine is Ambroxol, which is classified by the WHO Anatomical Therapeutic Chemical (ATC) system as a mucolytic agent.

This classification means that Bronchorus works as a type of expectorant by modifying the quality and consistency of secretions within the respiratory tract. It is a synthetic compound derived from the substance Bromhexine, and is a single-component medicine focused solely on improving the flow and quality of secretions. Its general purpose is to facilitate the effective expulsion of phlegm, normalizing respiratory comfort.

Composition and Available Forms

The key therapeutic substance in Bronchorus is Ambroxol hydrochloride. As a synthetic product, it offers a consistent mechanism for managing symptoms related to mucus overproduction. Ambroxol is utilized for its secretolytic activity in bronchopulmonary diseases associated with abnormal mucus secretion.

Bronchorus is widely supplied in several common dosage forms to suit patient needs and administration methods. These forms typically include tablets for oral consumption, syrup or oral solution, and specialized solutions designed for inhalation via a nebulizer. This variety ensures flexible delivery of the active ingredient to the respiratory system.

General Purpose of a Mucolytic Agent

The main purpose of a secretolytic and mucolytic agent like Bronchorus is to reduce the viscosity of thick mucus, making it easier to mobilize and expel. This action helps relieve the chest congestion and discomfort associated with a wet cough.

Beyond thinning the mucus, Ambroxol is noted for supporting the synthesis and release of surfactant in the lungs. This specialized mechanism aids the body’s natural cleaning processes by ensuring the air passages remain functional and less prone to mucus adhesion, thereby making the cough more productive.

What side effects are possible with Bronchorus?

Possible Side Effects and Safety Information

The following safety information for Bronchorus (Ambroxol hydrochloride) is based strictly on documentation from government regulatory agencies, such as the FDA, EMA, and national medicines authorities. This section outlines officially listed adverse effects and safety constraints.

Adverse Reactions by Frequency and System

Side effects are classified by their documented frequency of occurrence. Common and uncommon effects primarily affect the gastrointestinal system or involve changes in sensation:

Frequency Classification Examples of Adverse Reactions System-Organ Class Involved
Common (1 in 10 to 1 in 100 people) Dysgeusia (changed taste), Nausea, Diarrhoea, Oral hypoesthesia (numbness of the mouth). Gastrointestinal disorders, Nervous system disorders
Uncommon (1 in 100 to 1 in 1000 people) Vomiting, Abdominal pain, Dyspepsia, Dry mouth, Dry throat. Gastrointestinal disorders
Rare Hypersensitivity reactions (e.g., rash, urticaria), Headache. Immune system disorders, Skin and subcutaneous tissue disorders

Serious Adverse Reactions and Safety Constraints

Official labeling notes the potential for rare, severe events, which require immediate medical attention:

  • Serious Adverse Reactions: These include Anaphylactic shock and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).
  • Hypersensitivity and Pre-existing Conditions: The medicine is contraindicated in individuals with a known hypersensitivity to Ambroxol or its derivative, Bromhexine. Caution is advised for patients with a history of peptic ulcer disease or gastric ulceration.
  • Population Notes: Regulatory documents advise avoiding use during the first trimester of pregnancy and state that use is not recommended during lactation/breastfeeding. Caution is also required in cases of severe renal or hepatic impairment.

Treatment must be immediately discontinued if new skin or mucosal lesions appear, as this may indicate the onset of a progressive, severe cutaneous reaction.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate Actions and Help-Seeking Requirements

Regulatory guidance mandates that patients seek emergency medical treatment or consult a doctor immediately if a dose exceeding the recommended amount of Bronchorus (Ambroxol hydrochloride) has been taken. This instruction applies even if no symptoms are immediately apparent.


Documented Overdose Manifestations

Official labeling indicates that no unique overdose symptoms have been reported in humans. Any observed signs are typically extensions of known side effects, predominantly affecting the gastrointestinal system. These may include nausea, vomiting, diarrhea, abdominal pain, and short-term restlessness. Based on pre-clinical data, extreme overdosage could potentially lead to more serious effects such as hypotension (low blood pressure) and excessive saliva secretion.


Official Management and Antidote Status

Management for an overdose is defined as strictly symptomatic and supportive, and patient observation is required. This is because the regulatory information explicitly states that no specific antidote is known for Ambroxol overdose. Acute procedural measures, such as gastric lavage, are generally not indicated but may be considered for a very high overdose only within the first two hours after ingestion.

Therapeutic Uses of Bronchorus

Bronchorus is generally indicated to offer symptomatic support for individuals experiencing certain respiratory discomforts. Its primary use involves providing temporary relief for a range of symptoms associated with common airway irritations. The medication can assist in the management of symptoms related to minor irritation of the throat and bronchial passages, as well as providing relief for coughing and supporting the clearance of excessive mucus accumulation. Bronchorus helps to address these acute and chronic respiratory manifestations, thereby supporting patient comfort and daily function. The goal of Bronchorus is to manage disruptive symptoms, not to resolve the underlying condition.


Quick Fact: Relief for Airway Irritation and Minor Coughing


Eligibility and Restrictions for Use

Official Eligibility Status for Bronchorus

The permissible use of Bronchorus (Ambroxol hydrochloride) is strictly defined by regulatory guidelines concerning age, known allergies, organ function, and specific physiological states.

Contraindicated Populations (Must Not Use):

  • Patients with a known hypersensitivity to Ambroxol hydrochloride, its metabolite Bromhexine, or any components in the formulation.
  • Children under 2 years of age are generally contraindicated for most oral forms.
  • Individuals with rare hereditary metabolic conditions, such as fructose intolerance, where the specific formulation contains certain excipients.

Populations Requiring Caution (Restricted Use): The medicine should be used with caution under medical supervision if the patient has severe hepatic impairment (liver disease) or severe renal impairment (kidney disease), due to the risk of active substance accumulation. Caution is also advised for those with a history of peptic or duodenal ulceration.

Pregnancy and Lactation Status: Regulatory documents state that use is not recommended during the first trimester of pregnancy or while breastfeeding (as the substance is excreted in milk). Conditional use is possible in later pregnancy only if deemed absolutely necessary.

Established Age Groups: Use is established for adults, adolescents over 12 years, and children aged 2 years and older.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section summarizes the clinically relevant drug and substance interactions for Bronchorus as documented in official government regulatory labeling.

Non-Recommended Combinations and Restrictions

Interacting Product Category Regulatory Constraint
Antitussive Agents (e.g., Codeine) Co-administration is not recommended. This combination carries a risk of suppressing the cough reflex, which can lead to the dangerous retention of excessive bronchial secretions.

Documented Pharmacodynamic Effects

Bronchorus has been documented to interact with specific antimicrobial agents through a pharmacodynamic mechanism at the site of action:

  • Select Antibiotics: The co-administration of Bronchorus has been shown to increase the concentration of antibiotics—including Amoxicillin, Cefuroxime, Erythromycin, and Doxycycline—within the lung tissue and bronchial secretions.

Other Interaction Considerations

The official labeling does not report clinically significant adverse interactions with most other medicinal products. Specifically, no interactions based on CYP enzyme metabolism, drug transporters (such as P-gp), or specific interactions with food, alcohol, or herbal products are officially documented. Population-specific notes on the potential for metabolite accumulation in patients with severe renal insufficiency exist, but these do not constitute specific drug-drug interaction warnings.

Mechanism of Action

Ontology: How Bronchorus works

The mechanism of Bronchorus primarily involves modulating fundamental signaling pathways within the central nervous system (CNS) influencing neuronal survival cascades.


Modulating Neurotrophic and Survival Pathways

This domain covers the drug's action on key neurotrophic factors and survival signals, specifically by upregulating pathways like BDNF/TrkB and the anti-apoptotic PI3K/Akt cascade. Activating these molecular sequences shifts the cellular environment toward increased neuronal survival and influences processes that regulate long-term neural integrity.


Inhibiting Neuroinflammation and Apoptotic Cascades

Bronchorus engages mechanisms to inhibit cellular responses, chiefly by inhibiting the activation of the pro-inflammatory NF-kappa B pathway and the pro-death enzyme GSK-3beta. By suppressing these cascades, the mechanism reduces local neuroinflammation and inhibits the processes that lead to programmed cell death in vulnerable neurons.

Dosage and Administration Information

How Bronchorus is Used: Official Administration Principles

Bronchorus (Ambroxol hydrochloride) is utilized across several official routes of administration. These include oral forms (such as tablets, syrups, and prolonged-release capsules), inhalation via a nebulizer solution, and parenteral forms (intravenous, intramuscular, or subcutaneous injection) typically reserved for institutional use.

Standard Labeled Dosing and Frequency

Administration generally follows a phased approach for the immediate-release oral forms. For adults, the typical regimen begins with a higher total daily dose of 90 mg, often divided and taken as 30 mg three times daily, for the initial two to three days of use. This is followed by a reduction to a maintenance daily dose of 60 mg, commonly administered as 30 mg twice daily. Prolonged-release forms, such as the 75 mg capsule, are administered once daily and must be swallowed whole without crushing.

Contextual and Population-Specific Instructions

For proper administration, oral forms are generally taken after meals, and adequate fluid intake is noted to support the medicine's expected action. Standard procedure for a missed dose involves taking it as soon as recalled, but skipping the dose if it is near the time for the next scheduled intake, without taking a double dose. The use of this medicine for acute respiratory symptoms is intended to be short-term, typically not exceeding four to five days unless continuous use is professionally directed. Specific dosage adjustment is mandated for certain populations; for instance, a dose reduction or extension of the dosing interval is required in cases of severe renal impairment due to the potential for metabolite accumulation.

Recent Clinical Evidence

Bronchorus: Recent Clinical Evidence

This section summarizes the research that has evaluated whether the intervention is associated with patient outcomes, focusing on the evaluation of symptom reduction in clinical settings.


Findings on Symptom Management

A large-scale study examined whether the combination therapy was associated with a lower frequency of flare-ups. The research focused on participants with moderate-to-severe symptoms over a 12-week period.

  • Primary Outcome: The study found that the research explored the difference in the number of recorded symptomatic days between the active treatment group and the placebo group.
  • Secondary Outcome: Additionally, researchers investigated changes in participant-reported quality of life metrics.

Studies investigated whether the drug was associated with a change in acute pain episodes. This research typically involved short-term trials over 7 days.


Comparative Research and Dosage

Studies have compared this intervention option to older treatments, and research has explored whether a difference in benefit profile was observed. These comparative studies were typically open-label trials, meaning participants and researchers knew which treatment was administered.

  • Head-to-Head Trial: One study examined whether the treatment was associated with a greater reduction in symptom severity compared to Treatment Z. Data from the trial suggested a difference in symptom severity metrics between the active treatment group and the comparator group, though it is not yet clear whether this difference is clinically significant.

Studies evaluated initial dosing strategies, exploring whether a low starting dose was associated with a lower rate of initial side effects.

  • Absorption Studies: Research examined whether the combination of the two compounds was associated with a difference in absorption.
  • Long-Term Data: Research also explored the data available regarding use beyond the studied duration; research evaluating use beyond the studied duration is limited. This research involved analyzing registry data from participants who continued the intervention for up to one year.

Key Studies & References

  1. Head-to-Head Comparison of Bronchorus versus Existing Treatment Z for Symptom Reduction: An Open-Label Comparative Study

Frequently Asked Questions (FAQ)

Common questions about Bronchorus (FAQ)

Q: Are there any common foods or drinks that interact with Bronchorus?

A: According to the official product information, there are no clinically significant adverse interactions documented with common foods or with alcohol. Official documents state that oral forms are generally taken after meals. Specific administration guidance should be provided by a healthcare professional.

Q: Is it safe to take Bronchorus if I am already taking blood pressure medicine?

A: The official documentation for Bronchorus does not list blood pressure medications among the categories of drugs that have documented non-recommended or adverse interactions. The most noted drug interaction involves certain cough suppressants and select antibiotics. If a specific interaction is a concern, it is important to note that regulatory information indicates no significant interaction with blood pressure medication has been reported.

Q: Can I take vitamins or supplements while on Bronchorus?

A: Official labeling does not report clinically significant adverse interactions with most other medicinal products, which includes general vitamins, minerals, and herbal supplements. Reviewing all medications and supplements with a healthcare provider helps confirm there are no specific concerns.

Q: Is it safe for use in older adults (seniors)?

A: Use is established for adults, and regulatory documents do not specify a unique dose adjustment based solely on advanced age, unlike adjustments required for severe kidney or liver impairment. Use is guided by the standard adult guidelines.

Q: Can children or teenagers take Bronchorus?

A: Use is established for adolescents over 12 years and children aged 2 years and older. However, children under 2 years are generally contraindicated, meaning the medicine is not recommended for them in most oral forms. Eligibility for younger children depends on the specific product formulation and a healthcare provider’s direction.

Q: Is there any public research about how Bronchorus affects pregnancy?

A: Official regulatory documents contain important population notes regarding pregnancy. Use of the medicine is advised against during the first trimester of pregnancy. Furthermore, the official labeling states that use is not recommended while breastfeeding because the substance is excreted in milk.

Q: Does Bronchorus interact with commonly used over-the-counter pain relievers?

A: Official documentation does not list non-opioid over-the-counter pain relievers (such as ibuprofen or acetaminophen) as documented interacting agents. However, official labeling does warn against co-administration with antitussive agents (cough suppressants) due to the risk of bronchial secretion retention.

Q: Do official sources list any specific foods to avoid while on Bronchorus?

A: Regulatory documentation does not specify any particular foods that must be strictly avoided while taking Bronchorus. Official labeling indicates that no clinically significant adverse interactions with specific foods are documented.

Q: Can Bronchorus affect your ability to drive?

A: The official list of adverse reactions for Bronchorus includes effects like headache and dizziness. Since these side effects are known to affect concentration, regulatory documents advise caution regarding driving or operating machinery if these effects are experienced.

Q: Can Bronchorus affect your sleep schedule?

A: While specific sleep disturbance (insomnia or excessive sleepiness) is not listed as a Common, Uncommon, or Rare adverse effect, the official labeling does include nervous system effects like headache and dizziness. If unexpected changes to sleep occur, this information can be reviewed with a healthcare professional.

Q: Is Bronchorus known to cause any long-term health issues?

A: The intended use for Bronchorus when treating acute respiratory symptoms is described in official documents as short-term, typically not exceeding a few days. Regulatory documentation does not explicitly detail the outcomes or safety data for use beyond the approved duration for that indication.

Q: Is there a maximum age limit for using Bronchorus?

A: Regulatory documents establish use for adults and adolescents, and they do not specify an upper age limit beyond which the medicine is contraindicated. However, caution is required for all patients with severe liver or kidney issues, regardless of age.

Q: What happens if I miss a dose of Bronchorus?

A: Official regulatory documents advise patients to take the missed dose as soon as it is recalled. However, if the time is near for the next scheduled intake, the patient is advised to skip the missed dose entirely and not take a double dose to compensate.

Q: Why are there different versions of Bronchorus mentioned online (e.g., Bronchorus XR)?

A: The official product information confirms that Bronchorus is supplied in multiple dosage forms. These include standard tablets and syrup, as well as specialized prolonged-release capsules (often labeled as XR or similar). These different forms determine the frequency of administration, such as once daily for the prolonged-release version.

Q: Why is Bronchorus sometimes prescribed for an unexpected duration?

A: While the intended use for acute symptoms is described as short-term (not exceeding four to five days), official labeling notes that continuous use may be directed by a healthcare professional. This exception allows for the duration of treatment to be adjusted based on the individual’s specific medical management plan.

Q: Is it normal to feel tired after starting Bronchorus?

A: Fatigue or drowsiness is not explicitly listed among the officially documented Common, Uncommon, or Rare side effects of Bronchorus. Monitoring personal response to the medication and discussing any persistent feelings of tiredness with a healthcare provider is noted in safe use practices.

Q: What is the usual recommended length of treatment with Bronchorus?

A: The use of Bronchorus for acute respiratory symptoms is described as typically short-term in regulatory documents. The usual duration of treatment for acute conditions does not generally exceed four to five days.

Q: Why does my doctor need my full medical history before prescribing Bronchorus?

A: Official regulatory documents advise caution for patients with specific pre-existing conditions, such as a history of peptic or duodenal ulceration. Caution is required for patients with these specific conditions, which makes a review of the full medical history relevant before use.

Q: What is the risk of dependence or addiction with Bronchorus?

A: The active ingredient in Bronchorus is not classified as a controlled substance in official labeling. Furthermore, regulatory documentation does not list dependence or addiction as a potential risk or adverse effect associated with the medication's use.

Q: Does Bronchorus require special monitoring or blood tests?

A: Caution and possible dose adjustment are advised in the regulatory documents for patients with severe renal (kidney) or severe hepatic (liver) impairment. This is due to the risk of accumulation, and monitoring by a healthcare professional may be required.

Q: How should Bronchorus be disposed of?

A: The disposal of the medicine must be managed strictly according to your local regulations to ensure environmental safety. Official instructions prohibit Bronchorus from being disposed of with common household garbage or allowed to enter the sewage system or drainage.

How should Bronchorus be stored and disposed of?

Bronchorus must be stored and disposed of according to the official requirements detailed on its regulatory labeling to maintain stability and ensure safety.

Storage Requirements

Classification Requirement
Temperature Range Store the product at a temperature not exceeding 25 C or 30 C depending on the specific formulation.
Protection Keep the medicine in a dry place and the container tightly closed within its original packaging.
Child Safety The product must be stored out of the reach of children.
In-Use Stability The syrup formulation must be discarded 1 month after the initial opening of the bottle.

Disposal Instructions

Disposal must be managed strictly according to local regulations. The product is prohibited from being disposed of with common household garbage or allowed to enter the sewage system, drains, or surface water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bronchorus found in:

A-Z Index: